MatrileX Laboratories is pleased to announce the publication of our new peer-reviewed study, “Dose-dependent effects of the ACE inhibitor, ramipril, on kidney function and structure in the Alport COL4A3−/− mouse.”
The study defines, for the first time, the functional and structural dose–response relationship of ramipril in the Alport model. Cystatin C and proteinuria improved in a logarithmic, dose-dependent manner, with approximately 50% functional benefit at 1–3 mg/kg/day. In contrast, structural protection—including podocyte density, glomerulosclerosis, and tubulointerstitial fibrosis—was only evident at ≥3 mg/kg/day.
Implications
- 1 mg/kg/day is suitable for testing add-on therapies aimed at improving kidney function.
- 3 mg/kg/day is required to assess structural benefits of combination therapy.
This work improves the translational alignment between mouse and human ACE inhibitor responses and supports more predictive preclinical study design.
https://doi.org/10.1177/14703203251386305
